TrialThe oncologist2020

Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.

Barbara Melosky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.